이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Shenzhen Neptunus Interlong Bio-technique 미래 성장

Future 기준 확인 0/6

현재 Shenzhen Neptunus Interlong Bio-technique 의 성장과 수익을 예측할 만큼 분석가의 범위가 충분하지 않습니다.

주요 정보

n/a

수익 성장률

n/a

EPS 성장률

Pharmaceuticals 수익 성장	10.7%
매출 성장률	n/a
향후 자기자본 수익률	n/a
애널리스트 커버리지	None
마지막 업데이트	n/a

최근 미래 성장 업데이트

업데이트 없음

Recent updates

We Think You Can Look Beyond Shenzhen Neptunus Interlong Bio-technique's (HKG:8329) Lackluster Earnings

Apr 19

These 4 Measures Indicate That Shenzhen Neptunus Interlong Bio-technique (HKG:8329) Is Using Debt Safely

Oct 03

Is Shenzhen Neptunus Interlong Bio-technique (HKG:8329) A Risky Investment?

Mar 29

We Think Shenzhen Neptunus Interlong Bio-technique (HKG:8329) Can Stay On Top Of Its Debt

Sep 28

A Look At The Intrinsic Value Of Shenzhen Neptunus Interlong Bio-technique Company Limited (HKG:8329)

Aug 18

Does Shenzhen Neptunus Interlong Bio-technique (HKG:8329) Have A Healthy Balance Sheet?

Jun 06

Is Shenzhen Neptunus Interlong Bio-technique (HKG:8329) Using Too Much Debt?

Dec 15

Shenzhen Neptunus Interlong Bio-technique's(HKG:8329) Share Price Is Down 49% Over The Past Five Years.

Dec 29

Shenzhen Neptunus Interlong Bio-technique (HKG:8329) Seems To Use Debt Rather Sparingly

Nov 24

이 섹션에서는 일반적으로 투자자가 회사의 수익 창출 능력을 이해하는 데 도움이 되도록 전문 애널리스트의 컨센서스 추정치를 기반으로 수익 및 수익 성장 전망치를 제시합니다. 하지만 Shenzhen Neptunus Interlong Bio-technique 은 충분한 과거 데이터를 제공하지 않았고 애널리스트 예측도 없기 때문에 과거 데이터를 추정하거나 애널리스트 예측을 사용하여 미래 수익을 안정적으로 계산할 수 없습니다.

SimplyWall St에서 다루는 기업의 97%가 과거 재무 데이터를 가지고 있기 때문에 이는 매우 드문 상황입니다.

수익 및 매출 성장 예측

SEHK:8329 - 애널리스트의 미래 추정치 및 과거 재무 데이터 (CNY Millions )
날짜	수익	수익	잉여 현금 흐름	작전 현금	평균 애널리스트 수
3/31/2024	1,045	27	N/A	N/A	N/A
12/31/2023	1,065	24	38	54	N/A
9/30/2023	1,120	64	N/A	N/A	N/A
6/30/2023	1,103	64	-77	-56	N/A
3/31/2023	1,071	60	N/A	N/A	N/A
12/31/2022	987	54	42	61	N/A
9/30/2022	931	47	N/A	N/A	N/A
6/30/2022	886	37	46	60	N/A
3/31/2022	835	31	N/A	N/A	N/A
12/31/2021	839	36	-85	-70	N/A
9/30/2021	868	33	N/A	N/A	N/A
6/30/2021	963	38	-72	-42	N/A
3/31/2021	1,056	43	N/A	N/A	N/A
12/31/2020	1,031	37	56	94	N/A
9/30/2020	1,077	52	N/A	N/A	N/A
6/30/2020	1,065	59	118	156	N/A
3/31/2020	1,059	57	N/A	N/A	N/A
12/31/2019	1,081	60	27	60	N/A
9/30/2019	1,006	56	N/A	N/A	N/A
6/30/2019	937	52	-5	24	N/A
3/31/2019	879	47	N/A	N/A	N/A
12/31/2018	867	48	-3	25	N/A
9/30/2018	862	43	N/A	N/A	N/A
6/30/2018	848	43	-6	26	N/A
3/31/2018	835	51	N/A	N/A	N/A
12/31/2017	790	50	N/A	56	N/A
9/30/2017	803	64	N/A	N/A	N/A
6/30/2017	772	64	N/A	77	N/A
3/31/2017	777	65	N/A	N/A	N/A
12/31/2016	759	63	N/A	83	N/A
9/30/2016	738	37	N/A	N/A	N/A
6/30/2016	726	29	N/A	43	N/A
3/31/2016	713	20	N/A	N/A	N/A
12/31/2015	721	21	N/A	62	N/A
9/30/2015	664	19	N/A	N/A	N/A
6/30/2015	662	23	N/A	60	N/A
3/31/2015	650	31	N/A	N/A	N/A
12/31/2014	648	33	N/A	39	N/A
9/30/2014	633	30	N/A	N/A	N/A
6/30/2014	630	27	N/A	60	N/A
3/31/2014	603	37	N/A	N/A	N/A
12/31/2013	612	36	N/A	29	N/A
9/30/2013	582	34	N/A	N/A	N/A

애널리스트 미래 성장 예측

수입 대 저축률: 8329 의 예상 수익 증가율이 절약률( 2.2% )보다 높은지 판단하기에는 데이터가 부족합니다.

수익 vs 시장: 8329 의 수익이 Hong Kong 시장보다 빠르게 성장할 것으로 예상되는지 판단하기에는 데이터가 부족합니다.

고성장 수익: 8329 의 수익이 향후 3년 동안 상당히 증가할 것으로 예상되는지 판단하기에는 데이터가 부족합니다.

수익 대 시장: 8329 의 수익이 Hong Kong 시장보다 빠르게 성장할 것으로 예상되는지 판단하기에는 데이터가 부족합니다.

고성장 수익: 8329 의 수익이 연간 20% 보다 빠르게 증가할 것으로 예상되는지 판단하기에는 데이터가 부족합니다.

주당 순이익 성장 예측

미래 자기자본 수익률

미래 ROE: 8329 의 자기자본수익률이 3년 내에 높을 것으로 예상되는지 판단하기에는 데이터가 부족합니다.

Shenzhen Neptunus Interlong Bio-technique 미래 성장

Future 기준 확인 0/6

주요 정보

최근 미래 성장 업데이트

Recent updates

First quarter 2024 earnings released: EPS: CN¥0.012 (vs CN¥0.01 in 1Q 2023)

Shenzhen Neptunus Interlong Bio-technique Company Limited, Annual General Meeting, Jun 21, 2024

Shenzhen Neptunus Interlong Bio-technique Company Limited to Report Q1, 2024 Results on May 27, 2024

We Think You Can Look Beyond Shenzhen Neptunus Interlong Bio-technique's (HKG:8329) Lackluster Earnings

Full year 2023 earnings released: EPS: CN¥0.014 (vs CN¥0.032 in FY 2022)

Shenzhen Neptunus Interlong Bio-technique Company Limited to Report Fiscal Year 2023 Results on Mar 22, 2024

Third quarter 2023 earnings released: EPS: CN¥0.009 (vs CN¥0.009 in 3Q 2022)

Shenzhen Neptunus Interlong Bio-technique Company Limited to Report Q3, 2023 Results on Nov 07, 2023

These 4 Measures Indicate That Shenzhen Neptunus Interlong Bio-technique (HKG:8329) Is Using Debt Safely

Second quarter 2023 earnings released: EPS: CN¥0.008 (vs CN¥0.006 in 2Q 2022)

Shenzhen Neptunus Interlong Bio-technique Company Limited to Report First Half, 2023 Results on Aug 11, 2023

Shenzhen Neptunus Interlong Bio-Technique Company Limited Announces Appointment of Executive Director and Retirement of Non-Executive Director

Shenzhen Neptunus Interlong Bio-technique Company Limited, Annual General Meeting, Jun 21, 2023

First quarter 2023 earnings released: EPS: CN¥0.01 (vs CN¥0.006 in 1Q 2022)

Is Shenzhen Neptunus Interlong Bio-technique (HKG:8329) A Risky Investment?

Full year 2022 earnings released: EPS: CN¥0.032 (vs CN¥0.021 in FY 2021)

Less than half of directors are independent

Third quarter 2022 earnings released: EPS: CN¥0.009 (vs CN¥0.003 in 3Q 2021)

Shenzhen Neptunus Interlong Bio-technique Company Limited to Report Nine Months, 2022 Results on Nov 08, 2022

We Think Shenzhen Neptunus Interlong Bio-technique (HKG:8329) Can Stay On Top Of Its Debt

A Look At The Intrinsic Value Of Shenzhen Neptunus Interlong Bio-technique Company Limited (HKG:8329)

Second quarter 2022 earnings released

Shenzhen Neptunus Interlong Bio-technique Company Limited to Report First Half, 2022 Results on Aug 12, 2022

Does Shenzhen Neptunus Interlong Bio-technique (HKG:8329) Have A Healthy Balance Sheet?

Shenzhen Neptunus Interlong Bio-technique Company Limited, Annual General Meeting, Jun 24, 2022

First quarter 2022 earnings released

Shenzhen Neptunus Interlong Bio-Technique Company Limited Appoints Jin Rui as Non-Executive Director

Less than half of directors are independent

Full year 2021 earnings released

Shenzhen Neptunus Interlong Bio-technique Company Limited to Report Fiscal Year 2021 Results on Mar 31, 2022

Is Shenzhen Neptunus Interlong Bio-technique (HKG:8329) Using Too Much Debt?

Third quarter 2021 earnings released

Second quarter 2021 earnings released

First quarter 2021 earnings released

Full year 2020 earnings released

Shenzhen Neptunus Interlong Bio-Technique Company Limited Appoints Zhang Yi Fei as Non-Executive Director, Effective March 1, 2021

GM, Authorized Representative & Executive Director has left the company

Shenzhen Neptunus Interlong Bio-Technique Company Limited Announces Executive Changes

Shenzhen Neptunus Interlong Bio-technique's(HKG:8329) Share Price Is Down 49% Over The Past Five Years.

New 90-day low: HK$0.33

Shenzhen Neptunus Interlong Bio-technique (HKG:8329) Seems To Use Debt Rather Sparingly

Third quarter 2020 earnings released: EPS CN¥0.006

New 90-day high: HK$0.39

New 90-day high - HK$0.38

New 90-day high - HK$0.34

Earnings released

New 90-day high - HK$0.24

수익 및 매출 성장 예측

애널리스트 미래 성장 예측

주당 순이익 성장 예측

미래 자기자본 수익률

성장 기업 발견